BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:29 PM
Oct 01, 2012
 |  BC Extra  |  Clinical News

Bavarian Nordic reports preliminary CV-301 data

Bavarian Nordic A/S (CSE:BAVA) said CV-301 plus docetaxel led to progression-free survival of 6.6 months vs. 3.8 months for docetaxel alone in a Phase II trial to treat metastatic breast cancer (p=0.12). According to the company,...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >